DBP signed a "Memorandum of Understanding" with international partner regarding a possible licensing agreement on development of Temodex
Today, the 5thof April, DBP AB has signed a so-called "Memorandum of Understanding" (MoU) with a potential partner for the development of Temodex. Development involves clinical development, manufacturing, marketing, distribution and othr product-related activities. MoU describes the cooperation terms between DBP and the upcoming partner and can potentially lead to an exclusive license agreement on the development of Temodex. DBP builds today a portfolio of drug candidates for various types of cancers. These candidates should then be outlicensed for commercialization. Temodex - acting
